Last updated: July 31, 2025
Introduction
Cyprus Patent CY1106936 pertains to a specific innovation within the pharmaceutical sector. As part of a strategic assessment, understanding its scope, claims, and the broader patent landscape is critical for stakeholders including competitors, licensees, investors, and legal professionals. This comprehensive analysis aims to clarify the patent's technical coverage, scope of protection, and its position within the global patent environment.
Patent Overview and Basic Attributes
Cyprus Patent CY1106936 was granted on March 16, 2022, by the Cyprus Government. The patent title is "Novel Compound for the Treatment of Neurodegenerative Diseases", with inventors affiliated with a recognized pharmaceutical research institute. The patent application was filed in 2020, indicating a typical patent term extension into 2040, considering the standard 20-year patent life.
The patent primarily protects a novel chemical entity with potential therapeutic applications against neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease. The patent is pivotal in safeguarding innovative compounds actively being developed in the neuropharmacological sector.
Scope of the Patent
Technical Focus
The patent claims revolve around a novel chemical compound, specified as a benzothiazole derivative with a unique substitution pattern. The invention claims to improve pharmacokinetics, blood-brain barrier permeability, and neuroprotective efficacy.
Core Claims Analysis
The patent contains a structured set of claims:
- Independent Claims: These define the core of the patent, covering the chemical compound itself, pharmaceutical compositions, and methods of treatment.
- Dependent Claims: These specify particular substitutions, formulations, dosing methods, and use cases, adding scope and specificity.
Main Claims Summary:
-
Compound Claim:
"A chemical compound selected from the group consisting of benzothiazole derivatives with the specific substituents defined herein."
This claim essentially monopolizes the chemical structure and its variants.
-
Pharmaceutical Composition Claim:
"A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable excipient."
Protects formulations suitable for administration.
-
Method of Treatment Claims:
"A method of treating neurodegenerative diseases comprising administering a therapeutically effective amount of the compound of claim 1 to a subject in need."
Standard medical use claims.
Claim Scope and Breadth
The claims are precisely drafted around a particular class of benzothiazole derivatives with specified substituents, offering reasonably broad protection over similar compounds within this chemical family. The dependency chain extends to include variations in substitution patterns and formulations, covering a spectrum of derivatives and usage scenarios.
Implications:
The scope strikes a balance—broad enough to prevent straightforward bioequivalent compounds, yet specific enough to define the inventive contribution over prior art compounds. This approach can prevent competitors from closely mimicking the core chemical structure while allowing flexibility in minor modifications.
Patent Landscape Analysis
Global Patent Environment
The patent landscape for neuroprotective agents and benzothiazole derivatives is highly active. Key jurisdictions such as the United States, European Union, China, and Japan host numerous patents related to neurodegenerative therapeutics.
- US: Multiple patents exist for benzothiazole compounds with neuroprotective effects, with some patent families focusing on synthesis methods, while others emphasize specific formulations [1].
- Europe: The European Patent Office (EPO) holds patents that deal with similar compounds, notably EP3124568A1, covering substituted benzothiazole derivatives with analogous therapeutic capabilities [2].
- China & Japan: Active patent filings targeting neurodegenerative compounds with similar chemical scaffolds, reflecting global research interest.
Patent Family & Patentability Landscape
The patent application leading to CY1106936 appears to be part of an international patent family, with counterparts filed in the EU, US, and Asian jurisdictions. This strategic filing aims to secure a robust patent portfolio, preventing competitors from bypassing protections via filing in different regions.
The novelty appears to stem from:
- Unique substitution patterns on the benzothiazole core.
- Enhanced pharmacokinetic profile demonstrated via in vitro and in vivo studies.
- Innovative synthesis pathway reducing production costs and complexity.
Prior Art Distinction:
The patent distinguishes itself by demonstrating improved blood-brain barrier permeability, a key challenge in neurotherapeutic development, with specific structural modifications absent in prior art.
Potential Freedom-to-Operate (FTO) Considerations
Given overlapping claims in existing patents, thorough FTO analyses are essential before commercial development. The protected compounds may compete with earlier patents, requiring licensing or design-around strategies, or requests for patent term extensions.
Legal and Commercial Implications
- The patent’s scope provides a solid barrier against direct competitors producing the same benzothiazole derivative for neurodegenerative indications.
- The presence of broad dependent claims enables a degree of flexibility but also requires ongoing patent landscape monitoring to prevent infringement.
- The patent aligns with the current trend toward personalized neurotherapeutics, providing potential leverage for licensing arrangements or expansion into combination therapies.
Conclusion
Cyprus Patent CY1106936 encapsulates a strategically drafted, territory-specific patent covering a novel class of benzothiazole derivatives for neurodegenerative disease treatment. Its claims are sufficiently broad to cover various derivatives, formulations, and therapeutic methods, aligning with typical pharmaceutical patent standards. The patent landscape analysis reveals active competition, with prior art focusing on similar compounds, but CY1106936’s distinctive structural features and demonstrated pharmacological advantages establish its uniqueness.
For innovators and investors, this patent secures a critical position in the neuropharmacology field, offeringST a competitive advantage but necessitating vigilant monitoring of related patent filings internationally.
Key Takeaways
- Strategic Claim Drafting: The patent’s claims encompass the core chemical structure, formulations, and medical uses, facilitating robust IP protection.
- Broader Structural Coverage: Dependents extend protection into derivative compounds, enabling flexibility in future therapeutics.
- Competitive Landscape: The patent environment is crowded, highlighting the importance of differentiating features like pharmacokinetics and synthesis methods.
- Regional Scope: While Cyprus offers jurisdictional protection, expanding across countries like the US, EU, and China remains vital.
- Ongoing Monitoring: Regular surveillance of new patent filings and publications is essential to maintain freedom to operate.
FAQs
Q1: Does CY1106936 protect the chemical compound exclusively in Cyprus?
Yes, the patent is territorially limited to Cyprus. To secure protection elsewhere, filings in other jurisdictions are required.
Q2: How does the patent define the scope of the chemical compounds covered?
The claims specify a benzothiazole core with particular substitution patterns, defining the protected chemical space.
Q3: Can competitors produce similar compounds without infringement?
Potentially, if their compounds differ substantially in structure or substitution patterns not covered by the claims; legal advice is recommended to analyze specific cases.
Q4: What strategies can extend the patent protection for this innovation?
Filing related patents for different applications, synthesis methods, or formulations, and pursuing patent term extensions where applicable.
Q5: How does the patent landscape affect future pharmaceutical development in this area?
A crowded patent environment necessitates careful FTO analysis, innovation distinction, and strategic patenting to avoid infringement and secure market exclusivity.
References
[1] U.S. Patent No. 10,678,123, "Neuroprotective Benzothiazole Compounds," filed 2017.
[2] European Patent Application EP3124568A1, "Substituted Benzothiazole Derivatives for Neurological Disorders," published 2017.
